Dr Ross Salvaris

Learn more about Monash Health’s Haematology team.

Dr Ross Salvaris

Dr Ross Salvaris is a clinical and laboratory consultant haematologist with a special interest in clinical research in low-grade lymphoma. He completed a fellowship in lymphoma at Monash Health and Sir Charles Gairdner Hospital. He is an active member of the Australasian Leukaemia & Lymphoma Group working parties for chronic lymphocytic leukaemia and lymphoma and the Australasian Lymphoma Alliance. He aims to promote patient access to novel therapies through participation in clinical trials.

Recent publications

Salvaris RT, Brennan J, Lewis KL. BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL. Cancers. 2025; 17(3):557.

Salvaris RT, Allanson BM, Collins G, Cheah C. Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment. Haematologica. 2024 Nov 1;109(11):3476-3487.

Salvaris R, Allanson B, Cheah C. Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia. Leuk Lymphoma. 2023 Mar 24;1-5.

Salvaris R, Cheah C. Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma? Leuk Lymphoma. 2022 Dec;63(14):3271-3273.

Salvaris R, Salman S, O’Halloran S, Joyce D, Mathew N, Cooney J, Wright M, Cannell P, Purtill D. Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients. Blood Cell Ther. 2022 Apr 22;5(2):61-68.

Salvaris R, Fedele P. Targeted Therapy in Acute Lymphoblastic Leukaemia. J Pers Med. 2021 Jul 25;11(8):715.

Salvaris R, Ong J, Gregory G P. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. 2021 Apr 29;11(5):355.

Salvaris R, Opat S. An Update of Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukaemia. Future Oncology. 2021 Feb;17(4):371-387.